Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the U.S.

The following is a summary of “Patients with anti-PM/Scl-positive and idiopathic inflammatory myopathy resemble ...

The following is a summary of “Tacrolimus as first line therapy in a U.S. cohort of idiopathic inflammatory myopathies ...

Allogene Therapeutics is undervalued. Read more on ALLO stock's cash runway, innovative CAR-T therapies, and market expansion ...

Allogene Therapeutics Inc. surged over 42% last week amid a bullish analyst take on its latest immuno-oncology update and a ...

Idiopathic inflammatory myopathies (IIMs) are associated with autoantibodies against nuclear and cytoplasmic antigens. Myositis-specific autoantibodies (MSAs) are specific to patients with IIMs.

Limitations of these systems include vague phenotypic description, unclear exclusion criteria, exclusion of autoantibodies, and exclusion of some subgroups of idiopathic inflammatory myopathies.

The FDA has granted Fast Track designation to ADI-001 for the treatment of refractory systemic lupus erythematosus with extrarenal involvement.

Critical illness polyneuropathy (CIP) and critical illness myopathy (CIM ... of both disorders is complex and involves metabolic, inflammatory and bioenergetic alterations. It is unclear at ...

The idiopathic inflammatory myopathies (IIM) are a heterogeneous family of diseases that includes six major types: dermatomyositis (DM), antisynthetase syndrome (AS), immune-mediated necrotising ...